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Forced degradation study of quinapril by UPLC-DAD and UPLC/MS/MS: Identification of by-products 1 
and development of degradation kinetics  2 
 
Abstract 3 
Quinapril undergoes a significant degradation in the solid state, especially in the presence of humidity, 4 
temperature and pharmaceutical excipients. Since dissolution increases the degradation, hydrolytic reactions are 5 
among the most common processes involved in drug degradation. Improving the knowledge regarding drug 6 
stability, especially concerning the critical factors that can influence the stability of the active substance in 7 
solutions, such as the temperature, the pH and the concentration of catalytic species usually acids or bases is 8 
essential for pharmaceutical use; the aim of this study was therefore to develop a new chromatographic method 9 
for rapidly and accurately assess the chemical stability of pharmaceutical dosage in acidic, neutral and alkaline 10 
media at 80°C according to the ICH guidelines. Ultra High Performance Liquid Chromatography (UPLC) 11 
coupled to electrospray ionization tandem mass spectrometry was used for the rapid and simultaneous analysis of 12 
quinapril and its by-products. Separation was achieved using a BEH C18 column and a mixture of acetonitrile -13 
ammonium hydrogencarbonate buffer (pH 8.2; 10 mM) (65:35, v/v) with a flow rate of 0.4 mL/min as a mobile 14 
phase. This method allowed the drug by-products profiling, identification, structure elucidation and quantitative 15 
determination of by-products under stress conditions. The developed method also provides the determination of 16 
the kinetic rate constants for the degradation of quinapril and the formation of its major by-products. Kinetic 17 
study and the structure elucidation of by-products allow the development of a complete model including 18 
degradation pathway observed under all tested conditions.  19 
Keywords: Quinapril, Stress testing, ICH guideline (Q1A R2), UPLC-MS/MS, Degradation products, 20 
Degradation pathway. 21 
Introduction 22 
Quinapril (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-23 
isoquinolinecarboxylic acid hydrochloride [1-2] is a nonpeptide, nonsulfhydryl angiotensin converting enzyme 24 
inhibitor (ACEI) belonging to the third class of ACEI [2-4]. It is used for the treatment of cardiovascular 25 
diseases such as hypertension and congestive heart failure, either alone or in conjunction with other drugs [5-6]. 26 
Quinapril is an oral prodrug, yielding via metabolism a free active diacid compound, quinaprilat [4-7], which 27 
acts as an ACEI [8][9]. 28 
Previous studies showed that, like many dipeptide ACEI such as lisinopril [10], moexipril [11-13], enalapril 29 
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maleate [14], benazepril [15] and ramipril [16], quinapril hydrochloride is unstable in solid phase (in 30 
pharmaceutical dosage), especially in the presence of humidity, temperature, and pharmaceutical excipients [17-31 
18]. The influence of these factors on the stability of quinapril and the pathway characterizing its degradation in 32 
the solid phase were investigated by Beata Staniz [17-18]. Analysis of the degradation of quinapril in the solid-33 
state showed that Quinaprilat (hydrolysis product), the diketopiperazine ester (cyclization product) and the 34 
diketopiperazine acid (cyclization and hydrolysis product) were the main products [17-18]. 35 
Although a significant degradation occurs in the solid state, particularly in amorphous systems, the rate of drug 36 
degradation is faster in solution [19].  37 
Hydrolytic reactions are among the most common processes for drug degradation. Improving the knowledge 38 
regarding the critical factors that can influence the stability of the active substance in solution, such as 39 
temperature, pH and concentration of catalytic species usually acids or bases [20] are of major importance in 40 
pharmaceutical development, which include degradation studies in acidic, neutral and alkaline media. In fact, 41 
drug impurity profiling, identification, structure elucidation and quantitative determination of impurities and 42 
degradation products in bulk drug materials and pharmaceutical formulations is one of the most important fields 43 
of activities in modern pharmaceutical analysis. The reason for the increasing importance of this area is that 44 
unidentified, potentially toxic impurities are health hazards. Therefore, in order to increase the safety of drug 45 
therapy, impurities should be identified and determined by selective methods [20-22]. 46 
In the literature, there is no reported work on the chemical stability of quinapril under stress conditions. Further 47 
studies are therefore needed to characterize the by-products formed by quinapril degradation under acidic, 48 
neutral and alkaline media. According to the international conference on harmonization (ICH), accelerated 49 
stability studies have to be carried out, according to the stability test guideline Q1A (R2) [23] to establish its 50 
inherent stability characteristics, leading to the development of a separation method for the degradation products 51 
and hence to support the stability-indicating nature of the method.  52 
Many analytical methods have been reported in the literature for the analysis of quinapril such as gas 53 
chromatography with negative-ion chemical ionization mass spectrometry (MS) or electron-capture detection 54 
[24], capillary electrophoresis [25], high performance liquid chromatography with fluorescence [24], UV [2] or 55 
radiochemical detection [26] as well as electrospray ionization (HPLC/ESI) [2], and MALDI-TOF MS[27]. The 56 
considered techniques include also UV spectroscopy [28], square wave voltammetry [29], ultraperformance 57 
liquid chromatography tandem mass spectrometry (UPLC–MS/MS) [28], ultra-thin-layer chromatography mass 58 
spectrometry and thin-layer chromatography mass spectrometry [30]. However, to our knowledge, on the one 59 
3 
 
hand no study demonstrates the ability of ultra-performance liquid chromatography (UPLC) to resolve the 60 
separation of quinapril and its degradation products, and on the other hand the identification of the by-products 61 
has not been previously investigated. In order to better understand the mechanism of quinapril degradation, a 62 
chromatographic method involving diode array detector (DAD) and tandem mass spectrometry (MS-MS) has 63 
been therefore developed in this study. Degradation of quinapril according to the ICH guidelines has been 64 
performed and a complete mechanism for the quinapril degradation under basic, neutral and acidic conditions 65 
has been proposed. Since no data on kinetics of quinapril degradation could be found in the published literature, 66 
the purpose of this paper was also to present kinetic studies of disappearance and appearance of quinapril and 67 
major degradation products, respectively. 68 
2. Experimental conditions 69 
2.1. Chemical standards and solutions 70 
Quinapril was provided by the National laboratory of control of drugs and screening dopage (Tunisia). All 71 
mobile phase were prepared from reagent-grade chemicals and purified water (UPW) delivered by a Millipore 72 
system (MilliQ Elga, France). Acetonitrile (ACN) for UPLC-DAD and UPLC-MS/MS was purchased from 73 
Fisher Chemicals (HPLC grade, Loughborough, Leicestershire, UK) and JT Baker (LC-MS grade, United 74 
States), respectively. Aqueous solution of ammonium hydrogenocarbonate (Prolabo, Paris, France), (10 mM) 75 
was adjusted at pH = 8 ± 0.1 with a 911 pH meter (Knick, Germany). 76 
The mobile phases were filtered through a 0.2 μm cellulose acetate membrane filter (Sartorius stedim biotech, 77 
Goettingen, Germany) before filling the eluent organizer. 78 
2.2. Ultra Performance Liquid Chromatography – Diode Array Detector (ULPC-DAD)  79 
 Ultra performance liquid chromatography (UPLC) was performed using a Waters Acquity H-class system 80 
(Waters Corporation, Milford, MA). Samples and standards were maintained at 4°C in the sampler manager 81 
prior to analyses. 5 µL of samples were then injected into an Acquity BEH C18 column (100 x 2.1 mm, 1.7 µm, 82 
Waters) thermostated at 45°C. Different compositions of mobile phases were evaluated to achieve the separation 83 
of quinapril and its degradation products. The general composition of the eluent consisted of an UPW/ACN 84 
mixture. Effects of the ratio UPW/ACN, pH and addition of buffering species (ammonium hydrogencarbonate, 85 
formic acid) on the chromatographic separation were evaluated. Flow rate was set at 0.4 mL min
-1
 and detection 86 
was made between 190 and 500 nm. Waters Empower
TM 
chromatography software was used to control the 87 
chromatographic system and to record data.  88 
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2.3. Ultra Performance Liquid Chromatography – Tandem Mass Spectrometry (ULPC-MS/MS)  89 
Liquid Chromatography Tandem mass spectrometry system consisted of an Acquity UPLC system (Waters 90 
Corporation, Milford, MA) coupled with a triple quadrupole detector (Quattro premier, Micromass). 5 µL of 91 
samples from the hydrolytic degradation experiments were separated on an Acquity BEH C18 column (100 x 2.1 92 
mm, 1.7 µm, Waters). Isocratic separation was carried out with a mixture of eluent A (65%, vol.): eluent B (35% 93 
vol.) at a flow rate of 0.4 mL min
-1
. Eluent A consisted of an aqueous solution of ammonium hydrogencarbonate 94 
(10 mM, pH 8.1); eluent B was ACN. Sampler manager and column oven were kept at 4°C and 45°C, 95 
respectively. The MS analysis was performed by means of an electrospray ionization (ESI) interface both in 96 
positive or negative ion mode with a capillary voltage of ± 3 kV. Indeed, according to the quinapril structure 97 
both positive and negative modes could be applied, owing to the carboxylic and amide functional groups of 98 
quinapril which could give protons during the ionization process on the one hand, and since both molecules 99 
could be protonated on the other hand. In accordance with preliminary investigation as well as with literature 100 
data [1-2, 31], a positive mode was chosen. Product ion spectra of quinapril and its degradation products were 101 
acquired using N2 as nebulizer and drying gas. The cone gas flow and the desolvation gas flow were set to 50 L 102 
h
-1
 and 750 L h
-1
, respectively. The source temperature and the desolvation gas temperature were 120 °C and 350 103 
°C, respectively. The mass range (m/z) was 50-600. 104 
2.4. Stress study 105 
Stress studies were carried out under the conditions of heat and hydrolysis as mentioned in ICH Q1A (R2) 106 
guideline [23]. Hydrolytic decomposition of quinapril was performed at 80 °C with 0.1 N HCl, water and 0.1 N 107 
NaOH at an initial drug concentration of 0.5 mg mL
−1
 and 0.1 mg mL
-1
. However, because quinapril was found 108 
to be highly affected to alkaline degradation, studies were performed by reducing the concentration of sodium 109 
hydroxide to 0.01 N. The approach suggested by Bakshi and Singh [32] was adopted for this study. A minimum 110 
of four samples were generated for each stress condition; the blank solution stored under normal conditions, the 111 
blank subjected to the same stress  as the drug (quinapril), zero time sample containing the drug (which was 112 
stored under normal conditions), and the drug solution subjected to stress treatment. 113 
2.5. Separation study and development of stability-indicating method 114 
UPLC-DAD experiments were performed on all reaction solutions individually, and then on a mixture of 115 
degraded drug solutions. In order to obtain acceptable separation between quinapril and its degradation products, 116 
as well as between the different degradation products, different logical modifications like change in pH, mobile 117 
phase composition and column temperature adjustment were tested. To allow the transposition of the 118 
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chromatographic method from UPLC-DAD to UPLC-MS/MS simple rules should be respected; eluent 119 
composition must only involve volatile compounds to avoid salt deposit into the cone. In the first step, a mixture 120 
of UPW acidified at pH = 3 by formic acid and ACN was used as a mobile phase. Formic acid was selected 121 
because the apparent pKa of quinapril is equal to 5.7 and the conventional degradation pathway of ACEI leads to 122 
the formation of carboxylic acid by the ester function cleavage. However non-reproducible retention time and 123 
signals intensity were obtained with formic acid. Elution with ammonium hydrogencarbonate as the buffering 124 
compound led to more relevant results for the separation of quinapril from its degradation products; it also 125 
resulted in a retention time observed on the UPLC-DAD system comparable to that obtained in the UPLC-126 
MS/MS system. The selected composition of the mobile phase consisted therefore of a mixture of 65 % (vol.) 127 
ammonium hydrogencarbonate 10 mM in UPW and 35 % (vol.) of ACN with a flow rate of 0.4 mL min
-1
. From 128 
a practical standpoint, ammonium hydrogencarbonate is an ideal buffer for chromatographers since it provides 129 
excellent chromatographic behaviour and reproducible separation. Satisfactory results were obtained by the 130 
standard diode array and MS detection by using this buffer at a concentration of 10 mM. A major reason for 131 
using this concentration was to achieve maximum sensitivity of UV detection at low wavelengths. The detector 132 
was operated at 211 nm since this ACEI weakly absorbs in the UV region. This method was shown to provide 133 
fast and efficient separation of quinapril from its degradation products. In addition, hydrogencarbonate buffer is 134 
thermally decomposed in CO2 and NH3 in the MS interface since 60°C [33]. 135 
3. Results and discussion  136 
3.1. Degradation behaviour of quinapril under thermal hydrolysis (alkaline, neutral and acidic conditions)  137 
The estimation of the impurity profiles of bulk drug substances is one of the most important fields of activity in 138 
contemporary industrial pharmaceutical analysis. In general impurities present in excess of 0.1% should be 139 
identified and quantified by sufficiently selective methods, but drug registration authorities are increasingly 140 
interested by impurities in the range 0.01-0.1% for many reasons [21]. The guidance also indicates that 141 
degradation products that are not formed under accelerated or long term conditions do not need to be evaluated. 142 
Therefore, data from this study are typically used to evaluate quinapril stability. As shown in figure.1, all 143 
quinapril by-products detected under accelerated stability testing exceeded the identification thresholds in all 144 
stress conditions. 145 
Quinapril stability under various conditions (alkaline, neutral and acidic) at 80°C was assessed as mentioned 146 
above and the results of the stability studies are collected in figure.1. All experiments were conducted at two 147 
concentration levels of quinapril (0.114 mM in alkaline medium and 1.14 mM in neutral and acidic media). The 148 
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results indicated that quinapril is degraded under the various considered conditions. Chromatographic analysis 149 
showed that quinapril degradation occurred faster in alkaline medium compared to both acidic and neutral 150 
media. Under alkaline conditions, quinapril degradation was observed from the first minutes yielding the 151 
formation of two by-products eluted at a retention time of 0.55 and 0.66 min respectively. The chromatogram, 152 
obtained on a C18 column (Figure 1.a), shows a very broad peak relative to the quinapril (RT= 1.35 min, ω= 153 
0.48 min) and a peak splitting relative to the by-product eluted at 0.66 min. This chromatographic phenomenon 154 
may be attributed to an equilibrium between the cis- and the trans-conformers that arose from the hindered 155 
rotation around the amide bond having partial double bond character. It is consistent with studies showing that 156 
similar chromatographic phenomenon has been observed with other ACEI such as enalapril [34], enalaprilat [35] 157 
and lisinopril [36]. However, additional experiments by LC-DAD, which could be later considered, are needed to 158 
confirm this assumption.  159 
Acidic and neutral hydrolysis at 80°C led to the formation, within the first minutes, of a major by-product eluted 160 
at 8.92 min. Other degradation products were also observed but after a significant contact time. The full scan 161 
spectra were recorded for solutions obtained after 22 h of contact with 0.1 M HCl and water. As shown in fig. 1 162 
the chromatographic method was able to resolve all the components in a mixture of stressed sample. The peaks 163 
associated to degradation products were not only well-resolved from the drug, but also from one another. The 164 
method thus proved to be selective and stability-indicating either for the study of acidic, neutral and alkaline 165 
hydrolysis. On the other hand, reversed-phase UPLC conditions provided a general measure of the polarity of 166 
each compound, useful for the interpretation of substructural differences between related compounds.  167 
Comparison of chromatograms obtained under acidic and neutral conditions shows that quinapril present the 168 
same UPLC profile in the two media (same retention time and same UV spectra). Nevertheless, the rate of 169 
degradation under acidic hydrolysis is faster than under neutral hydrolysis. After a contact time of 23 hours 170 
approximately 89 % of the initial amount of quinapril has been degraded under neutral conditions leading to the 171 
formation of 5 separated by-products (Fig. 1.c). The UPLC profile obtained for the neutral degradation of 172 
quinapril revealed that among these products, four are eluted within only one minute retention time, namely 173 
before the starting material, indicating that these products are more polar than quinapril. These products 174 
corresponded to 6% of the amount of degraded quinapril after 24 h contact time, whereas the major by-product 175 
eluted at 8.92 min corresponded to 81% of that amount.   176 
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Under acidic conditions, 99 % of the drug was degraded after 24 h contact time at 80°C. Similarly to the neutral 177 
conditions, the by-product eluted at 8.92 min was the major product with an amount of 70% of the degraded 178 
quinapril, whereas the other by-products corresponded to only 9 % of the degraded drug. 179 
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Fig. 1. Chromatograms of quinapril and its degradation products obtained under alkaline (a), acid (b) and neutral 
(c) conditions at T = 80 °C for 23 h contact time and an initial amount of 500 mg/L, using an UPLC/UV method 
on a BEH C18 column (1.7 μm, 2.1 mm? ?? 100 mm) (Waters). Mobile phases: acetonitrile- ammonium 
hydrogencarbonate (pH = 8.2; 10 mM) -35:65, v/v). Flow rate: 0.4 mL/min. Wavelenght: 211 nm. Column 
temperature: 45°C. 
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Direct UV-vis spectrophotometric method shows that quinapril and its by-products present similar UV spectra 180 
with a benzenoid proﬁle (Appendix A, Fig. A.1). These spectra are characterized by weak shoulders at high 181 
wavelength values (> 250 nm). It can be therefore concluded that this method was not suitable, neither for 182 
qualitative nor quantitative analysis of quinapril in a mixture of potential degradation products, since it caused a 183 
problem of interference. To overcome this problem, due to degradation products other than analytes derivative 184 
spectroscopy can be used as a qualitative and quantitative method [37-39]. On the other hand, this technique 185 
proved its ability for analysis of benzenoid drugs such as ACE-inhibitors [39] whose UV spectra exhibit a partial 186 
fine vibrational structure.   187 
In order to investigate the ability of derivative spectrophotometric methods to measure the quinapril response in 188 
the presence of all the potential by-products, the derivative mode 
1
D, 
2
D, 
3
D and 
4
D (first, second, third and 189 
fourth-order derivative spectra), followed by currently used UPLC-DAD method were therefore plotted against 190 
wavelength. The degree of derivation was chosen in order to improve the resolution and the sensitivity of 191 
overlapping absorption and to find differences between UV spectra shapes of quinapril and its by-products. As 192 
can be seen from (Appendix A, fig.A.2), the derivation process allowed the conversion of large bands to sharp 193 
and intense peaks. Derivative UV spectra of quinapril and its by-products were quite similar and presented the 194 
same maximum of absorption except the degradation product eluted at 0.53 min. For instance, the second-order 195 
UV spectra of quinapril and its by-products exhibited intense peaks. As a result, derivative UV 196 
spectrophotometric method cannot be applied for quantitative or qualitative analysis of quinapril in the presence 197 
of its degradation products, due to the interference that can occur. In conclusion, the characteristic profile of the 198 
derivative spectra may not constitute a specific method useful to confirm drug identity and purity; no decrease in 199 
the amount of quinapril can be observed owing to its interference with degradation products. 200 
In spite of the similarity of UV visible absorption and response factor of related compounds, their MS ionization 201 
efficiencies can be significantly different. The target degradation products under study have been therefore 202 
differentiated thereafter as DPx for acidic and neutral conditions and DPxb for alkaline medium. 203 
3.2. Identification of degradation products of quinapril by UPLC-MS/MS 204 
UPLC-MS/MS has become a powerful technique to determine drugs in various matrix, specific fragmentation 205 
pattern give selectivity and sensitivity and allow the accurate determination of numerous drugs such as ACEI 206 
[31][40]. The use of UPLC-MS/MS is particularly relevant for the elucidation of impurities and degradation 207 
product structures and to propose degradation mechanisms [41-43]. Last years, many studies have employed the 208 
LC-MS/MS technique in order to evaluate ACEI stability and to characterize their degradation products [42, 44-209 
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45]. In order to elucidate the structure of degradation products induced by thermal hydrolysis process, LC-MS 210 
and LC-MS/MS substructural analysis methods have been therefore developed. These methods include 211 
information on molecular structures, chromatographic behaviour, molecular weight and MS/MS substructural 212 
information. 213 
Using ammonium hydrogencarbonate as the mobile phase, the chromatographic method previously described 214 
was directly transferred from LC-DAD to LC-MS/MS. Due to its volatility, ammonium hydrogencarbonate is 215 
being an essential buffering specie for rapid LC-MS product identification [33]. However, formation of 216 
ammonium adducts could make more complex the MS/MS interpretation [40]. In a first time, full-scan UPLC-217 
MS/MS of the degradation mixture ([QUI]0 = 500 mg/L; [HCl] = 0.1 M; contact time = 23 h; T = 80°C) has been 218 
performed and showed that retention times observed for quinapril and the major degradation products were close 219 
to those obtained by LC-DAD.  220 
MS spectra were acquired for each chromatographic peak. To further elucidate the structure of these degradation 221 
products, the MS/MS spectra (Appendix B, fig B.1 and fig B.2) of these products were acquired in an additional 222 
run with collision energy of 20 eV. This enabled to determine the elemental composition for the product ions of 223 
degradation products. The observed m/z values for molecular ion peak and major fragments of the quinapril and 224 
its degradation products under acidic and neutral media are listed in Table.1. These results prove that the same 225 
by-products were obtained under acidic and neutral conditions, with m/z values equal to m/z 252 (DP1), 178 226 
(DP2), 280 (DP3), 393 (DKPA), and 421(DPK). It should be noted that ammonium adducts [M+NH4]
+
 was not 227 
observed. 228 
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Table 1. Observed m/z values for the [M+H]
 +
 ions and major fragments of quinapril and its by- products in 229 
acidic, neutral and alkaline media. 230 
Degradation 
products 
Retention 
time (min) 
[M+H
+
] Fragment 
ion 
Fragment ion 
intensity (%) 
Proposed elemental 
composition 
 
DP1 
 
0.53 
 
252 
206 
160 
117 
102 
91 
100 
19 
15 
30 
5 
C12H16NO2 
C11H14N 
C9H9 
C4H8NO2 
C7H7 
DP2 0.68 178 132 100 C9H10N 
 
 
 
DP3 
 
 
 
0.74 
 
 
 
280 
234 
206 
160 
130 
117 
91 
50 
100 
13 
10 
25 
5 
C14H20NO2 
C12H16NO2 
C10H12NO2 
C11H14N 
C9H9 
C7H7 
 
 
DKPA 
 
 
0.93 
 
 
393 
375 
347 
319 
231 
117 
91 
60 
10 
5 
70 
100 
1 
C23H23N2O3 
C22H23N2O2 
C21H23N2O 
C13H14N2O2 
C9H9 
C7H7 
 
 
Quinapril 
 
 
1.37 
 
 
439 
365 
234 
206 
160 
130 
117 
102 
8 
78 
2 
4 
5 
3 
2 
C22H25N2O3 
C14H20NO2 
C12H16NO2 
C11H14N 
C6H12NO2 
C9H9 
C4H8NO2 
12 
 
 
 
DKP 
 
 
8.92 
 
 
421 
375 
347 
319 
231 
117 
91 
95 
13 
5 
100 
50 
2 
C23H23N2O3 
C22H23N2O2 
C21H23N2O 
C13H14N2O2 
C9H9 
C7H7 
PD2b 0.55 411 365 
206 
178 
160 
102 
2.5 
30 
3.75 
1 
2 
C22H25N2O3 
C12H16NO2 
C10H13NO2 
C11H14N 
C4H8NO2 
PD1b 0.67 411 365 
206 
178 
160 
102 
2.5 
31 
4 
0.5 
1 
C12H16NO2 
C10H13NO2 
C11H14N 
C4H8NO2 
C4H8NO2 
PD1'b 0.76 411 365 
206 
178 
160 
102 
2.5 
32 
2.5 
1.25 
1 
C22H25N2O3 
C12H16NO2 
C10H13NO2 
C11H14N 
C4H8NO2 
 
In order to elucidate the structures of quinapril by-products, the first step was to understand the fragmentation 231 
pattern of the parent-drug substance. Indeed, the detailed mass spectrometry analysis of the fragmentation 232 
pattern of quinapril provides a basis for assessing structural assignment for the degradation products. As can be 233 
seen from Table 1, the fragmentation pattern for drug displayed the same behavior as reported by Burinsky and 234 
Sides [31] and Vikas shinde et al [2]. Indeed, the (+) ESI-MS/MS spectrum of quinapril, with a protonated 235 
molecular ion at m/z 439, showed a series of fragment ions of m/z values of 365, 234, 170, 160, 134, 130 and 236 
117. The fragment ion with m/z 365, which was 74 Da less than the quinapril ion, resulted from the loss of the 237 
ester side chain (OCOCH2CH3). The most intense fragment at m/z 234 resulted from the cleavage of the bond 238 
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between the carbon atom of the amide group and the α-carbon, followed by further loss of CH2=CH2 to yield m/z 239 
206 and subsequent elimination of styrene to produce m/z 102. Finally, the subsequent fragments at m/z 160, 240 
134 and 117 originated from the aliphatic chain reduction from the product-ion m/z 206 (Fig. 2). 241 
 242 
Fig. 2. Fragmentation pattern for quinapril (m/z 439) and some degradation products; DP3 (m/z 280) 243 
and DP1 (m/z 252) 244 
 
According to the structure of quinapril, cyclization, ester and amide bond hydrolysis were the possible 245 
degradation pathway that can be foreseen. However, from Table 1 only two major degradation pathways of 246 
quinapril in acidic and neutral media were observed; cyclization was the main pathway, while hydrolysis of the 247 
amide bond was only observed at low levels in the samples.  248 
The degradation product eluted at 8.92 min retention time, exhibited the same MS
1
 spectrum with a molecular 249 
ion at m/z 421, both under acidic and neutral conditions. The MS
2
 spectrum obtained by fragmentation of the 250 
m/z 421 ion led to a series of atypical ions (m/z 375, 347, 319, 231, 117, 91) (Fig.3) compared to quinapril 251 
fragmentation. With respect to the MS
2
 spectrum (Appendix B, Fig. B.3), the mechanism of fragmentation 252 
presented in fig. 4 can be suggested from the diketopiperazine product (DKP). Formation of the diketopiperazine 253 
product requires deprotonation of the reacting amine followed by the addition of neutral nitrogen to the carbonyl 254 
of the neighboring carboxylic acid to form a tetrahedral intermediate, which then loses water to give the 255 
diketopiperazine product. Similar results were observed for some ACE inhibitors such as moexipril [46], 256 
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enalapril [47], lisinopril [48], ramipril [46, 49], xpril and perindopril [50] which yield to the diketopiperazine 257 
product under acidic and neutral conditions.  258 
The compound eluted at a retention time of 0.93 min with a protonated molecular m/z 393 was 28 Da less than 259 
quinapril diketopiperazine. 28 Da corresponded to the loss of CH2=CH2 to yield to the diketopiperazine acid 260 
product (C23H24N2O4). This product characterized by the same fragment ions as quinapril diketopiperazine, can 261 
result from the hydrolysis of the ester function of DKP or cyclization of the diacid product with an m/z value of 262 
411. However, the diacid product of quinapril was not detected both in neutral and acidic media. In order to 263 
confirm that the diacid product of quinapril with m/z value of 411 is not coeluted,a LCMS
1 
attempts were made 264 
to follow the "LC/MS profile" of this compound (m/z=411). Results obtained proved that this product was not 265 
detected neither in acid medium nor neutral medium. 266 
The last hypothesis was a direct transformation of the diacid product to yield DKPA. A simulation study could 267 
be later considered to confirm or deny this assumption. 268 
 
 269 
 
Fig. 3. Fragmentation pattern for degradation products DKP and DKPA with m/z 421 and 393, 270 
respectively 271 
 
The second possible pathway of degradation, namely a hydrolysis of the amide bond, was confirmed by the 272 
presence of two degradation products DP2 and DP3 with protonated molecular [M+H
+
], m/z 178 and 280, both 273 
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in neutral and acidic media. This result was in agreement with other findings [51-52], showing that the cleavage 274 
of the peptide bond is a common degradation pathway of peptides and proteins. Based on the MS
2
 spectra 275 
(Appendix B, Fig. B.3), the elemental composition for these ions were C10H11NO2 and C15H21NO4 for m/z 178 276 
and 280, respectively. The DP3 with an m/z value of 280 was characterized by a series of fragments 234, 206, 277 
160, 130, 117, 91. The most intense fragment (m/z 206) corresponded to the loss of 74 Da relative to the ester 278 
function followed by further loss of formic acid (46 Da). Furthermore, the other fragments at m/z 130, 117and 91 279 
were characteristics of intact part of the molecule (C9H12N). Except the fragment ion m/z 130, the by-product 280 
DP1, which differed from DP3 by 28 Da, displayed the same fragment ions characteristic of the intact part. 28 281 
Da corresponded to a loss of an ethyl group generated by hydrolysis of an ester function.  According to the 282 
elemental composition of this product, it can be assumed that this diacid product can be derived from the 283 
cleavage of the amide bond of the active metabolite quinaprilat or the hydrolysis of the ester function of the DP3 284 
by-product with m/z 280 (fig.2).  285 
These results seem to be in accordance with some studies showing that cyclization and amide bond hydrolysis 286 
occurred under acid and neutral conditions. In fact, it is well documented in the literature that dipeptides and 287 
proteins readily cyclize to diketopiperazine derivate and underwent a hydrolysis of the amide bond [51] [53]. 288 
The present work also shows that the rate of cyclization competes favorably with hydrolysis, in agreement with 289 
previous findings dealing with the forced degradation of some ACEI, namely fosinopril and enalapril maleate 290 
[52, 47]. These studies proved that the main decomposition route was the internal aminolysis reaction, producing 291 
the diketopiperazine and that the amide bond tends to cleave in acidic and neutral media. However, under these 292 
conditions ramipril and moexipril yield only the DKP product [48].  293 
Because very low amounts of DP3 and DP4 were observed during the thermal hydrolysis, it is inferred that 294 
hydrolysis of this bond was slower than the formation of diketopiperazine. It is in agreement with earlier 295 
investigations showing that internal aminolysis of dipeptide methyl esters and amides to form diketopiperazine 296 
was much faster than the hydrolysis of ester and amide functionalities [53]. 297 
The exclusive formation of by-products with m/z 411 under alkaline conditions was in agreement with previous 298 
investigations which demonstrated that the ester function of enalapril maleate, ramipril and moexipril undergo 299 
hydrolysis to yield the dicarboxylic form of ACEI [47-48]. MS
2
 analysis of these by-products shows the same 300 
ion fragments (365, 206, 178, 160,102). These products are relative to the quinaprilat and its isomers. The DP1b 301 
was characterized by a peak splitting, most likely due to the presence of the two conformers s-cis and s-trans 302 
around the amide bond N-C=O. Analysis by LC/MS and LC/DAD confirmed that the peak splitting was due to 303 
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the presence of two conformers. In fact, the purity of the peak relative to quinaprilat was checked by comparing 304 
the UV spectra and by examination of the MS spectra.  In addition, the effect of various operating conditions on 305 
the retention peak, namely splitting and bond broadening of quinaprilat and quinapril, have been qualitatively 306 
examined. This study provided more practical experimental conditions, allowing both the elution of quinaprilat 307 
and quinapril as single peaks, while keeping at the same time an acceptable separation. The effect of various 308 
factors on the conformational equilibrium s-cis/s-trans of quinapril and quinaprilat, namely the composition of 309 
the mobile phase, flow rate, and column temperature was investigated and the results are shown in the supporting 310 
information. The degradation product eluted at 0.55 min retention time shows the same fragmentation pattern as 311 
quinaprilat and can result from the epimerization of the DP1; about 25% of the observed degradation in 0.01 N 312 
NaOH was epimerized (Fig. 1.a). However, due to the lack of authentic isomers (RSS, SRR, SRS), the nature of 313 
the epimer cannot be elucidated.  314 
Similar results have been reported on moexiprilat degradation in 0.1 N KOH by Gu et al [54]. 315 
3.3 Mechanism and kinetic of quinapril degradation  316 
Structural elucidation of by-products led to the proposal of the degradation mechanism given in Fig. 4. It is 317 
postulated that cyclization is the major degradation process of quinapril under acidic and neutral conditions. 318 
Formation of diketopiperazine is followed by the hydrolysis of the ester function to lead to the diketopiperazine 319 
acid. Cleavage of the amide bond constitutes the second pathway of degradation of quinapril. In fact, the amide 320 
bond undergoes hydrolysis to lead to the two by-products DP3 and DP2 with m/z 280 and 178 respectively. Thus 321 
the DP1 by-product is generated from the hydrolysis of the ester function of DP3. Therefore, quinapril undergoes 322 
hydrolysis of the ester function only under alkaline conditions.   323 
In order to check the possibility of cyclization of quinaprilat to yield DKPA, two successive reactions were 324 
performed. These reactions consisted of an alkaline hydrolysis (NaOH 0.01 N) of quinapril at 80 °C, until the 325 
started material was exhausted, followed by an acidic hydrolysis (HCl 0.1N) at the same temperature. Analysis 326 
of the chromatographic profile of quinaprilat under acidic conditions by LC/DAD and LC/MS shows that DKPA 327 
was the major by-product formed.  The kinetic study by the chromatographic method shows that the constant 328 
rate of the formation of DKPA was 3.9 10
-3
 h
-1
.  329 
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 Fig. 4. A proposed degradation pathway of quinapril under acidic (HCl (0.1N)), neutral and alkaline (NaOH 330 
(0.01N)) conditions at 80°C. 331 
 
To elucidate the pathways of quinapril decomposition under the studied conditions, the concentration-time 332 
profiles of quinapril and major degradation products would be relevant. The kinetic of degradation of quinapril 333 
was investigated under different conditions (acid, neutral and alkaline) and after exposure to heating at 80°C. 334 
The remaining quinapril after various storage intervals was assessed by the stability-indicating UPLC method 335 
mentioned above. At various contact times, 300 µL of solution was transferred into vials conserved in an ice bath 336 
(-7°C) in order to stop the reaction. Samples were then immediately analysed by UPLC-DAD in order to 337 
determine the remaining concentration of quinapril. However, in alkaline medium, the rate of quinapril 338 
degradation was much faster than in neutral and acidic media. Quinapril reaction was followed for 2 hours in 339 
alkaline medium, while it was followed for 24 hours in neutral and acidic media. Fig. 5 (Curves in point form) 340 
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shows a typical time course of disappearance of quinapril and formation of its major degradation products 341 
detected under the studied media. Main products were quinaprilat and its isomers products in alkaline medium, 342 
and both DKP and DKPA in acid and neutral media. Accordingly, cyclization of quinapril was much faster than 343 
hydrolysis of amide and ester bonds under acidic and neutral media.  344 
As quinaprilat and quinaprilat isomers were only formed under basic medium, only the ester bond hydrolysis 345 
was considered. In all conditions, quinapril concentration decreased exponentially with time and since 346 
hydrochloric acid, water and sodium hydroxide are in large excess with respect to quinapril, the kinetics would 347 
be a typical pseudo-first-order process. This kinetic behaviour was compatible with earlier reports for other ACE 348 
inhibitors, such as enalapril maleate [50] [55], xpril, perindopril [50] [56], benazepril [57] and moexipril [12]. 349 
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Fig. 5. Degradation of quinapril ([QUI]0 = 500 ppm= 1.14 mM) at T = 80 °C under alkaline (a), acidic (b) 
and neutral (c) conditions. Experimental concentration-time profiles for quinapril, and diketopiperazine 
product (left axis) and degradation product (m/z 393) (right axis) 
 
Fig.6 confirmed that at 80°C quinapril degraded faster under alkaline conditions compared to acidic and neutral 350 
conditions. The apparent first-order degradation rate constants  at 80°C were calculated and found to be 0.19 h
−1
 351 
(t1/2= 3.70 h), 0.086 h
-1
 (t1/2= 8.02 h) and 1.12 h
−1
 (t1/2= 0.62 h) for acidic, neutral and 352 
alkaline degradation processes, respectively. These results proved that quinapril was more stable under neutral 353 
conditions, in agreement with previous works dealing with enalapril maleate [41], xpril and perindopril [37][44], 354 
and benazepril [50]. 355 
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Fig. 6. First-order plots for the rate of disappearance of quinapril under alkaline, acidic ([HCl] = 0.1 M) and 
neutral conditions ([QUI]0 = 500 ppm = 1.14 mM at 80°C). 
 
3.5. Degradation pathway of quinapril  356 
Kinetic model was developed according to the proposed degradation pathway of quinapril under all 357 
consideration media. Only the main product (quinaprilat, DKP and DKPA) were considered in the kinetic model. 358 
COPASI 4.8 [58] was used to calculate the rate constant from the experimental data point and to simulate the 359 
degradation curves of quinapril and the formation of DKP and DKPA. In order to fit the rate constants to 360 
experimental data, it was assumed that the molar extinction coefficient of quinapril and its by products were 361 
similar. Because cyclisation of quinapril or quinaprilat to form DKP or DKPA requires the protonation of the 362 
carboxylic formation, acid-base equilibria of quinapril and quinaprilat were considered. Rate constant were 363 
determined by the least square method using the evolutionary programming method for parameters optimization 364 
using COPASI software. Degradation rate constant of quinapril to form quinaprilat and quinaprilat isomers was 365 
determined by considering only the experiment under alkaline conditions. Other degradation rate constants (k1, 366 
k2) were evaluated with multiple experimental parameters (estimation formation considering experimental data 367 
point from acid and neutral conditions). Values and SD obtained for the kinetic rate constant were reported in 368 
fig. 4. A complete model including degradation pathway observed under all tested conditions was then 369 
developed and used to simulate the degradation curves of quinapril and the formation of the main by-products 370 
(Fig. 5). The proposed kinetic model allowed an accurate description of quinapril degradation.   371 
Modelling the degradation curves to the equation rates that describe the reaction pathways proposed allowed to 372 
check the assumption given in fig.4. Curves (in continuous lines) under neutral and acidic media are given in fig. 373 
5. The rate constants of disappearance of quinapril and the appearance of quinapril DKP, quinapril DKPA and 374 
quinaprilat were fitted. Pseudo-first-order kinetics were observed in all cases, and the rate constants (k1 and k2) 375 
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were determined and found to be 0.177±0.001 h
-1
, 3.79 10
-3
±1.04.10
-3
, respectively. However quinaprilat was not 376 
formed, neither under acidic medium nor under neutral medium. So, k1.[QH] was far superior to k3[Q
-
] (QH and 377 
Q
-
 are respectively the protonated and  unprotonated forms of quinapril respectively). Therefore, the DKPA 378 
formed during the degradation of quinapril must result from the hydrolysis of DKP rather than from the 379 
cyclization of quinaprilat. It was consistent with previous investigations demonstrating that ester and amide 380 
functional groups of dipeptides undergo intramolecular aminolysis at a much faster rate than hydrolysis [51]. 381 
Conclusion 382 
The development of a stability-indicating UPLC assay method for quinapril allowed the separation of the drug 383 
and its by-products formed under various stress conditions. 384 
Quinapril was found to be unstable in solution showing the formation of five degradation products. Structural 385 
elucidation performed by UPLC-MS-MS confirmed the presence of known by-products and allowed to propose 386 
the structure of unknown products. Comparison of the stability of quinapril under solution and solid states 387 
showed that kinetics and by-products distribution were altered. 388 
Through detailed kinetic study and by-products distribution a complete model including degradation pathway 389 
observed under all tested conditions was developed.   390 
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